<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01218685</url>
  </required_header>
  <id_info>
    <org_study_id>BUTVAC-Influenza A (H1N1) 2.0</org_study_id>
    <nct_id>NCT01218685</nct_id>
  </id_info>
  <brief_title>Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants</brief_title>
  <official_title>Evaluation Aof Safety and Immunogenicity of Non-adjuvanted Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants, Produced by Butantan Institute</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Butantan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Insituto Adolfo Lutz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro de Referencia e Treinamento em DST/AIDS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Butantan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to describe the safety and immunogenicity of a non-adjuvanted
      vaccine against pandemic influenza A (H1N1)in patients with chronic and or immunocompromised
      disease, elderly and pregnants. The primary immunological endpoint is to analyze the
      proportion of subjects with antibody titers of 1:40 or more on hemagglutination-inhibition
      assay 21 days after 1 dose of the vaccine. Volunteers will be monitored for safety during 21
      days after vaccination. Volunteers will be recruited based on inclusion and exclusion
      criteria. Vaccine composition is: 15 micrograms of split inactivated virus
      (A/California/7/2009 (H1N1) (NYMC X179A). The hypothesis of the study is that the vaccine is
      safe and immunogenic in the volunteers recruited.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody titers of 1:40 or more for influenza A pandemic (H1N1)</measure>
    <time_frame>21 days after vaccination</time_frame>
    <description>the proportion of subjects with antibody titers of 1:40 or more on hemagglutination-inhibition assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of the vaccine</measure>
    <time_frame>21 days after vaccination</time_frame>
    <description>Evaluation of local and systemic adverse effects through the study period including 30 minutes after vaccination</description>
  </secondary_outcome>
  <number_of_groups>9</number_of_groups>
  <enrollment type="Actual">1152</enrollment>
  <condition>Immunocompromised Patients</condition>
  <condition>Safety of Pandemic Influenza A (H1N1)Vaccine</condition>
  <condition>Immunogenicity of Pandemic Influenza A (H1N1)Vaccine</condition>
  <arm_group>
    <arm_group_label>Health adults</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Health children</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregnants</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly over 65 years old</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Kidney transplant</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Oncologic patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Rheumatologic adult patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Rheumatologic children patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS</intervention_name>
    <description>1 full dose of 15 micrograms, IM, for volunteers 9 years of age or older; children 6 months to 2 years of age, half of the dose,IM, with 21 days interval; children 3 years old up to 8 years old, 1 full dose, IM, twice, with 21 days interval.</description>
    <arm_group_label>Health adults</arm_group_label>
    <arm_group_label>Health children</arm_group_label>
    <arm_group_label>Pregnants</arm_group_label>
    <arm_group_label>Elderly over 65 years old</arm_group_label>
    <arm_group_label>HIV patients</arm_group_label>
    <arm_group_label>Kidney transplant</arm_group_label>
    <arm_group_label>Oncologic patients</arm_group_label>
    <arm_group_label>Rheumatologic adult patients</arm_group_label>
    <arm_group_label>Rheumatologic children patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Volunteers with chronic and or immunocompromised disease, elderly and pregnant in follow -
        up at the institutions participants in the study will be recruited.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Volunteers able to understand and agree to participate in the study.

        Exclusion Criteria:

          -  Have egg allergy

          -  Have past history of allergy to seasonal influenza vaccine

          -  Have received another inactivated vaccine within the prior 2 weeks or live vaccine in
             the past four weeks to his/her participation in the study

          -  Acute infectious disease during seven days prior vaccination

          -  Confirmed prior infection by pandemic influenza A (H1N1)

          -  Have participated in another clinical trial in the last 6 months

          -  Any other condition identified by the principal investigators which is considered not
             safe for enrollment of the volunteer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Roberto Precioso, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Butantan Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Avenida Vital Brasil 1500</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05503-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2010</study_first_submitted>
  <study_first_submitted_qc>October 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2010</study_first_posted>
  <last_update_submitted>February 5, 2013</last_update_submitted>
  <last_update_submitted_qc>February 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunocompromised patients</keyword>
  <keyword>Safety of pandemic influenza A (H1N1)vaccine</keyword>
  <keyword>Immunogenicity of pandemic influenza A (H1N1)vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

